Table 2.
Net benefit of RYR preparations in lipid profile in placebo-controlled trials
| No. of subjects | Baseline | Post-treatment | Difference | P value | ||
| Mean (SD) | Mean (SD) | Mean (95% CI) | % Change | |||
| TC levels (mmol/L) | ||||||
| Cholestin | 42 | 6.47 (0.78) | 5.43 (0.80) | -1.04 (-1.38 to -0.70) | -16% | < 0.00001 |
| Placebo | 41 | 6.59 (0.75) | 6.47 (0.93) | -0.12 (-0.49 to 0.25) | -2% | 0.52 |
| 30 | 6.68 (0.98) | 5.31 (0.84) | -1.37 (-1.83 to -0.91) | -21% | ||
| 33 | 5.81 (0.63) | 4.26 (0.63) | -1.55 (-1.85 to -1.25) | -27% | ||
| Xuezhikang | 101 | 7.30 (1.40) | 5.90 (1.40) | -1.40 (-1.79 to -1.01) | -19% | |
| 30 | 5.65 (1.31) | 3.16 (1.31) | -2.49 (-3.15 to -1.83) | -44% | ||
| Subtotal: 194 | -1.63 (-2.00 to -1.26) | < 0.00001 | ||||
| 28 | 6.72 (0.97) | 6.43 (0.93) | -0.29 (-0.79 to 0.21) | -4% | ||
| 30 | 5.84 (0.67) | 4.94 (0.67) | -0.90 (-1.24 to -0.56) | -15% | ||
| Placebo | 51 | 6.80 (1.40) | 6.70 (1.40) | -0.10 (-0.64 to 0.44) | -1% | |
| 20 | 5.55 (1.02) | 4.95 (1.02) | -0.60 (-1.23 to 0.03) | -11% | ||
| Subtotal: 129 | -0.50 (-0.90 to -0.11) | 0.01 | ||||
| 9 | 5.90 (0.95) | 4.94 (0.65) | -0.96 (-1.71 to -0.21) | -16% | ||
| Zhibituo | 30 | 6.70 (1.10) | 5.80 (0.90) | -0.90 (-1.41 to -0.39) | -13% | |
| 104 | 7.10 (1.70) | 5.60 (1.30) | -1.50 (-1.91 to -1.09) | -21% | ||
| Subtotal: 143 | -1.17 (-1.59 to -0.74) | < 0.00001 | ||||
| 9 | 5.83 (0.57) | 5.56 (0.53) | -0.27 (-0.78 to 0.24) | -5% | ||
| Placebo | 30 | 6.70 (1.50) | 6.40 (1.30) | -0.30 (-1.01 to 0.41) | -4% | |
| 101 | 6.00 (1.80) | 6.50 (0.70) | 0.50 (0.12 to 0.88) | 8% | ||
| Subtotal: 140 | 0.02 (-0.56 to 0.60) | 0.95 | ||||
| TG levels (mmol/L) | ||||||
| Cholestin | 42 | 1.50 (0.54) | 1.40 (0.50) | -0.10 (-0.32 to 0.12) | -7% | 0.38 |
| Placebo | 41 | 1.61 (0.52) | 1.65 (0.53) | 0.04 (-0.19 to 0.27) | 2% | |
| 30 | 2.84 (0.57) | 2.38 (0.62) | -0.46 (-0.76 to -0.16) | -16% | ||
| 33 | 2.10 (0.92) | 1.82 (0.92) | -0.28 (-0.72 to 0.16) | -13% | ||
| Xuezhikang | 101 | 3.60 (2.40) | 2.30 (1.60) | -1.30 (-1.86 to -0.74) | -36% | |
| 30 | 2.62 (0.58) | 1.47 (0.58) | -1.15 (-1.44 to -0.86) | -44% | ||
| Subtotal: 194 | -0.78 (-1.26 to -0.31) | 0.001 | ||||
| 28 | 2.74 (0.73) | 2.57 (0.69) | -0.17 (-0.54 to 0.20) | -6% | ||
| Placebo | 30 | 2.14 (0.94) | 1.91 (0.94) 3.00 (1.60) | -0.23 (-0.71 to 0.25) -0.30 (-0.92 to 0.32) | -11% | |
| 51 | 3.30 (1.60) | 3.00 (1.60) | -0.30 (-0.92 to 0.32) | -9% | ||
| 20 | 2.50 (0.50) | 2.11 (0.50) | -0.39 (-0.70 to -0.08) | -16% | ||
| Subtotal: 129 | -0.29 (-0.49 to -0.09) | 0.005 | ||||
| 13 | 2.46 (1.23) | 1.79 (0.57) | -0.67 (-1.41 to 0.07) | -27% | ||
| Zhibituo | 30 | 3.40 (0.90) | 2.10 (1.10) | -1.30 (-1.81 to -0.79) | -38% | |
| 104 | 3.40 (1.50) | 2.30 (1.30) | -1.10 (-1.48 to -0.72) | -32% | ||
| Subtotal: 147 | -1.10 (-1.38 to -0.82) | < 0.00001 | ||||
| 9 | 2.56 (0.88) | 2.36 (0.64) | -0.20 (-0.91 to 0.51) | -8% | ||
| 30 | 3.40 (1.10) | 3.10 (1.20) | -0.30 (-0.88 to 0.28) | -9% | ||
| Placebo | 101 | 3.10 (0.40) | 2.50 (1.40) | -0.60 (-0.88 to -0.32) | -19% | |
| Subtotal: 140 | -0.50 (-0.74 to -0.26) | < 0.0001 | ||||
| LDL-C levels (mmol/L) | ||||||
| Cholestin | 42 | 4.47 (0.70) | 3.49 (0.70) | -0.98 (-1.28 to -0.68) | -22% | < 0.00001 |
| Placebo | 41 | 4.65 (0.78) | 4.53 (0.85) | -0.12 (-0.47 to 0.23) | -3% | 0.51 |
| 30 | 3.94 (0.82) | 2.83 (0.88) | -1.11 (-1.54 to -0.68) | -28% | ||
| 33 | 4.13 (0.52) | 2.80 (0.52) | -1.33 (-1.58 to -1.08) | -32% | ||
| Xuezhikang | 101 | 4.80 (1.60) | 3.50 (1.40) | -1.30 (-1.71 to -0.89) | -27% | |
| 30 | 3.00 (1.03) | 2.10 (1.03) | -0.90 (-1.42 to -0.38) | -30% | ||
| Subtotal: 194 | -1.23 (-1.41 to -1.05) | <0.00001 | ||||
| 28 | 4.13 (0.94) | 4.01 (0.86) | -0.12 (-0.59 to 0.35) | -3% | ||
| 30 | 4.24 (0.53) | 3.41 (0.53) | -0.83 (-1.10 to -0.56) | -20% | ||
| Placebo | 51 | 4.20 (1.60) | 4.30 (1.60) | 0.10 (-0.52 to 0.72) | 2% | |
| 20 | 3.19 (0.87) | 2.70 (0.87) | -0.49 (-1.03 to 0.05) | -15% | ||
| Subtotal: 129 | -0.38 (-0.83 to 0.07) | 0.10 | ||||
| Zhibituo | 104 | 3.70 (1.60) | 3.50 (1.40) | -0.20 (-0.61 to 0.21) | -5% | 0.34 |
| Placebo | 101 | 3.70 (1.20) | 3.70 (1.00) | 0.00 (-0.30 to 0.30) | 0% | 1.00 |
| HDL-C levels (mmol/L) | ||||||
| Cholestin | 42 | 1.29 (0.34) | 1.29 (0.36) | 0.00 (-0.15 to 0.15) | 0% | 1.00 |
| Placebo | 41 | 1.19 (0.26) | 1.19 (0.28) | 0.00 (-0.12 to 0.12) | 0% | 1.00 |
| 30 | 1.50 (0.46) | 1.67 (0.54) | 0.17 (-0.08 to 0.42) | 11% | ||
| 33 | 1.37 (0.21) | 1.16 (0.21) | -0.21 (-0.31 to -0.11) | -15% | ||
| Xuezhikang | 101 | 1.20 (0.40) | 1.40 (0.30) | 0.20 (0.10 to 0.30) | 17% | |
| 30 | 1.20 (0.21) | 1.22 (0.21) | 0.02 (-0.09 to 0.13) | 2% | ||
| Subtotal: 194 | 0.04 (-0.17 to 0.24) | 0.73 | ||||
| 28 | 1.57 (0.69) | 1.53 (0.32) | -0.04 (-0.32 to 0.24) | -3% | ||
| 30 | 1.36 (0.24) | 1.13 (0.24) | -0.23 (-0.35 to -0.11) | -17% | ||
| 51 | 1.30 (0.40) | 1.30 (0.30) | 0.00 (-0.14 to 0.14) | 0% | ||
| Placebo | 20 | 1.22 (0.25) | 1.00 (0.25) | -0.22 (-0.37 to -0.07) | -18% | |
| Subtotal: 129 | -0.13 (-0.26 to -0.01) | 0.04 | ||||
| 13 | 0.89 (0.41) | 1.09 (0.41) | 0.20 (-0.12 to 0.52) | 22% | ||
| 30 | 1.08 (0.11) | 1.31 (0.17) | 0.23 (0.16 to 0.30) | 21% | ||
| Zhibituo | 104 | 0.85 (0.14) | 0.98 (0.26) | 0.13 (0.07 to 0.19) | 15% | |
| Subtotal: 147 | 0.18 (0.10 to 0.26) | < 0.0001 | ||||
| 13 | 0.92 (0.19) | 0.90 (0.17) | -0.02 (-0.16 to 0.12) | -2% | ||
| 30 | 0.99 (0.20) | 1.02 (0.28) | 0.03 (-0.09 to 0.15) | 3% | ||
| Placebo | 101 | 0.89 (0.13) | 0.80 (0.30) | -0.09 (-0.15 to -0.03) | -10% | |
| Subtotal: 144 | -0.04 (-0.12 to 0.03) | 0.26 | ||||